Friday - October 23, 2026

Cholangiocarcinoma Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The Cholangiocarcinoma Clinical Trial Analysis Report delivers important insights into ongoing research on 55+ pipeline drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 22, 2026, DelveInsight’s “Cholangiocarcinoma Pipeline Insight 2026” report provides comprehensive insights into 55+ … Continue reading →

Small Cell Lung Cancer Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and Route of Administration Trends | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca

(Albany, New York) – October 22, 2026: As per DelveInsight’s assessment, globally, Small Cell Lung Cancer pipeline constitutes 100+ key companies continuously working towards developing 100+ Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, … Continue reading →

Endometriosis Pain Pipeline Insights 2026: Novel Mechanisms, Promising Candidates, and Competitive Landscape by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie

(Albany, New York) – October 22, 2026: As per DelveInsight’s assessment, globally, Endometriosis Pain pipeline constitutes 5+ key companies continuously working towards developing 5+ Endometriosis Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Ovarian Cancer Pipeline 2026: Emerging Drugs, Regulatory Milestones, and Strategic Moves by Leading Players | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact

(Albany, New York) – October 22, 2026: As per DelveInsight’s assessment, globally, Ovarian Cancer pipeline constitutes 180+ key companies continuously working towards developing 200+ Ovarian Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Hidradenitis Suppurativa Market Set for Robust Expansion at a rapid CAGR Through 2036: Key Drivers, Trends, and Leading Players | AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, UCB Bio

The Key Hidradenitis Suppurativa Companies in the market include – Kymera Therapeutics, CSL Behring, Azora Therapeutics, Union Therapeutics, Eli Lilly and company, Boehringer Ingelheim, ACELYRIN, Incyte Corporation, InflaRx, Novartis, ChemoCentryx, Janssen Pharmaceutical/XBiotech, Aclaris Therapeutics, and others . (Albany, New York) … Continue reading →

Brain Metastases Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The Brain Metastases clinical trial analysis report delivers important insights into ongoing research on 40+ pipeline Brain Metastases drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 22, 2026, DelveInsight’s “Brain Metastases Pipeline Insights 2026” report provides … Continue reading →

Chronic Spontaneous Urticaria Clinical Trials Update 2026: Phase-Wise Pipeline Status, Drug Profiles, and Key Developers | Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly

(Albany, New York) – October 22, 2026: As per DelveInsight’s assessment, globally, Chronic Spontaneous Urticaria pipeline constitutes 20+ key companies continuously working towards developing 25+ Chronic Spontaneous Urticaria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of … Continue reading →